Susan M. Domchek

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Invest where impact begins: recommendations from Breast Cancer Research Foundation Early Career Investigator Working Group (Part 1 of 2)

  UNC Libraries · 2026-06-13

• Prevalence of <scp> <i>Helicobacter pylori</i> </scp> Exposure and Risk Factors Among <scp> <i>BRCA1</i> </scp> and <scp> <i>BRCA2</i> </scp> Carriers

  International Journal of Cancer · 2026-06-12

• Longitudinal Association of Quantitative Background Parenchymal Enhancement with Breast Cancer Risk Among Women with BRCA1/2 Pathogenic Variants

  Cancer Epidemiology Biomarkers & Prevention · 2026-06-10

• Risk Stratification for Breast Cancer Screening: <i>AJR</i> Expert Panel Narrative Review

  American Journal of Roentgenology · 2026-05-06

• Combining multiplexed assays of variant effect for enhanced BRCA2 variant classification

  Nature Communications · 2026-04-09 · 1 citations

• Large-scale meta-analysis and precision functional assays identify FANCM regions in which PTVs confer different risks for ER-negative and triple-negative breast cancer.

  Apollo (University of Cambridge) · 2026-01-09

• Supplementary Table S3 from The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib

  2025-12-17

• Supplementary Table S4 from The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib

  2025-12-17

• Supplementary Table S1 from The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Rucaparib

  2025-12-17

• Figure S1 from &lt;i&gt;NBN&lt;/i&gt; Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and &lt;i&gt;In Vitro&lt;/i&gt; DNA Damage Response Defects

  2025-11-25

• Figure S7 from &lt;i&gt;NBN&lt;/i&gt; Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and &lt;i&gt;In Vitro&lt;/i&gt; DNA Damage Response Defects

  2025-11-25

• Figure S2 from &lt;i&gt;NBN&lt;/i&gt; Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and &lt;i&gt;In Vitro&lt;/i&gt; DNA Damage Response Defects

  2025-11-25

• Supplementary Tables S1-S11 from &lt;i&gt;NBN&lt;/i&gt; Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and &lt;i&gt;In Vitro&lt;/i&gt; DNA Damage Response Defects

  2025-11-25

• Figure S4 from &lt;i&gt;NBN&lt;/i&gt; Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and &lt;i&gt;In Vitro&lt;/i&gt; DNA Damage Response Defects

  2025-11-25

• Figure S6 from &lt;i&gt;NBN&lt;/i&gt; Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and &lt;i&gt;In Vitro&lt;/i&gt; DNA Damage Response Defects

  2025-11-25

• Figure S3 from &lt;i&gt;NBN&lt;/i&gt; Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and &lt;i&gt;In Vitro&lt;/i&gt; DNA Damage Response Defects

  2025-11-25

• Figure S5 from &lt;i&gt;NBN&lt;/i&gt; Pathogenic Germline Variants are Associated with Pan-Cancer Susceptibility and &lt;i&gt;In Vitro&lt;/i&gt; DNA Damage Response Defects

  2025-11-25

• Clinical trial protocol1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer

  2025-11-25

• Supplementary Figure 1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer

  2025-11-25

• Supplementary Table 1 from Combination ATR (ceralasertib) and PARP (olaparib) Inhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian Cancer

  2025-11-25